Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
АТХ:B.02.B.D.01 Factors of blood coagulation IX, II, VII and X in combination
B.02.B.D Coagulation factors
Pharmacodynamics:In the human body is converted into activated factor IX and in combination with factor VIII promotes platelet adhesion. In the zone of vascular damage, platelet aggregation activates, which causes the prothrombin to pass into thrombin and promotes the formation of a fibrin clot. Increases in blood plasma levels of vitamin K-dependent factors of blood coagulation (II, VII, IX, X). By replenishing the deficiency of clotting factors reduces the risk of bleeding.
Pharmacokinetics:After intravenous administration of the drug in the blood serum, about 30-40% of the coagulation factors are determined, then the haemostatic activity gradually decreases.
Half-life for factors II, VII, IX, X is 40-60 minutes, 3-5 hours, 16-30 hours, 30-60 hours respectively.
Indications:It is used for the treatment and prevention of bleeding with congenital deficiency of one or several factors: factor II, factor IX, factor X. It is used to treat and prevent bleeding in patients with vitamin K deficiency and liver diseases. Used to treat bleeding when syndrome of disseminated intravascular coagulation, as well as hemophilia A and B.
III.D65-D69.D65 Disseminated intravascular coagulation [defibrillation syndrome]
III.D65-D69.D67 Hereditary deficiency of factor IX
III.D65-D69 Blood clotting disorders, purpura and other hemorrhagic conditions
III.D65-D69.D68 Other coagulation disorders
IV.E50-E64.E56.1 Insufficiency of vitamin K
III.D65-D69.D69.9 Hemorrhagic condition, unspecified
III.D65-D69.D69.8 Other specified hemorrhagic conditions
XXI.Z100.Z100 * CLASS XXII Surgical Practice
Contraindications:High risk of thrombosis, individual intolerance.
Carefully:Pregnancy and lactation, the period of newborns, the postoperative period, ischemic heart disease, myocardial infarction in the anamnesis, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C.It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.
Dosing and Administration:Intravenously, for the purpose of replacement therapy, depending on the severity of the clinical picture, the laboratory parameters of blood, volume and localization of bleeding.
For patients taking oral anticoagulants - for 35-50 IU / kg.
When syndrome of disseminated intravascular coagulation and liver diseases, the initial dose is 50 IU / kg, if necessary, repeated administration after 6-12 hours.
With inhibitory forms of hemophilia A and B, 75 IU / kg every 8-12 hours.
Side effects:Local Reactions: burning sensation at the injection site.
General reactions: hyperthermia.
Allergic reactions.
Overdose:Myocardial infarction, vein thrombosis, pulmonary embolism.
Treatment is symptomatic.
Interaction:It is forbidden to mix the drug with other medicines in the same syringe, infusion solution.
Special instructions:In the treatment it is not recommended to drive vehicles and work with moving mechanisms.